Cargando…
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer
BACKGROUND: Chemoradiation therapy (CRT) has been increasingly reported as a possible alternative to total cystectomy (TC) for localized bladder cancer (BC). Pembrolizumab is the standard of care for platinum-refractory metastatic urothelial carcinoma, although it is unknown whether the efficacy of...
Autores principales: | Nishimura, Kazuki, Nishio, Kyosuke, Hirosuna, Kensuke, Komura, Kazumasa, Hayashi, Takuo, Fukuokaya, Wataru, Ura, Ayako, Uchimoto, Taizo, Nakamura, Ko, Fukushima, Tatsuo, Yano, Yusuke, Takahashi, Nobushige, Nakamori, Keita, Kinoshita, Shoko, Matsunaga, Tomohisa, Tsutsumi, Takeshi, Tsujino, Takuya, Taniguchi, Kohei, Tanaka, Tomohito, Uehara, Hirofumi, Takahara, Kiyoshi, Inamoto, Teruo, Hirose, Yoshinobu, Kimura, Takahiro, Egawa, Shin, Azuma, Haruhito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765067/ https://www.ncbi.nlm.nih.gov/pubmed/35039462 http://dx.doi.org/10.1136/jitc-2021-003868 |
Ejemplares similares
-
Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan
por: Uchimoto, Taizo, et al.
Publicado: (2021) -
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Uchimoto, Taizo, et al.
Publicado: (2021) -
CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer
por: Tsujino, Takuya, et al.
Publicado: (2021) -
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
por: Komura, Kazumasa, et al.
Publicado: (2023) -
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort
por: Komura, Kazumasa, et al.
Publicado: (2019)